Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Upgrades Ecolab to Outperform, Raises Price Target to $185

RBC Capital analyst Ashish Sabadra upgrades Ecolab (NYSE:ECL) from Sector Perform to Outperform and raises the price target from $155 to $185.
byBenzinga Newsdesk
February 15, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

RBC Capital analyst Ashish Sabadra upgrades Ecolab (NYSE:ECL) from Sector Perform to Outperform and raises the price target from $155 to $185.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca Announced Enhertu Granted Priority Review in the US for Patients with HER2-low Metastatic Breast Cancer

By Charles Gross
July 25, 4:55 AM
AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the US with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridisation [ISH]-negative) breast cancer who have received a prior therapy in the metastatic set

AZN